Patents by Inventor Antonio J. Grillo-Lopez

Antonio J. Grillo-Lopez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODY
    Publication number: 20130273039
    Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.
    Type: Application
    Filed: April 23, 2013
    Publication date: October 17, 2013
    Inventor: Antonio J. Grillo-Lopez
  • USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT
    Publication number: 20130273041
    Abstract: The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.
    Type: Application
    Filed: June 10, 2013
    Publication date: October 17, 2013
    Applicant: BIOGEN IDEC, INC.
    Inventors: Antonio J. GRILLO-LOPEZ, John LEONARD
  • Treatment of vasculitis
    Patent number: 8545843
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: October 1, 2013
    Assignees: Genentech, Inc., Biogen Idec Inc.
    Inventors: John G. Curd, Antonio J. Grillo-Lopez
  • Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
    Patent number: 8329172
    Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.
    Type: Grant
    Filed: August 18, 2007
    Date of Patent: December 11, 2012
    Assignee: Biogen Idec
    Inventor: Antonio J. Grillo-López
  • COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODY
    Publication number: 20120258101
    Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.
    Type: Application
    Filed: June 15, 2012
    Publication date: October 11, 2012
    Inventor: Antonio J. Grillo-López
  • COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODIES
    Publication number: 20120258102
    Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.
    Type: Application
    Filed: June 15, 2012
    Publication date: October 11, 2012
    Inventor: Antonio J. Grillo-López
  • COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODY
    Publication number: 20120251535
    Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.
    Type: Application
    Filed: June 15, 2012
    Publication date: October 4, 2012
    Inventor: Antonio J. Grillo-López
  • COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODY
    Publication number: 20120251534
    Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.
    Type: Application
    Filed: June 15, 2012
    Publication date: October 4, 2012
    Inventor: Antonio J. Grillo-Lopez
  • TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20120201818
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: April 18, 2012
    Publication date: August 9, 2012
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies
    Patent number: 8206711
    Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: June 26, 2012
    Assignees: Biogen Idec Inc., Genentech, Inc.
    Inventors: Christine A. White, Antonio J. Grillo-Lopez, John G. Curd, Susan Desmond-Hellmann
  • USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT
    Publication number: 20110165159
    Abstract: The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.
    Type: Application
    Filed: March 18, 2011
    Publication date: July 7, 2011
    Applicant: Biogen Idec Inc.
    Inventors: Antonio J. Grillo-López, John Leonard
  • Treatment of Autoimmune Diseases
    Publication number: 20110008337
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 13, 2011
    Applicant: Genetech, Inc.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Treatment of Autoimmune Diseases
    Publication number: 20110008250
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 13, 2011
    Applicant: Genentech, Inc.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Treatment of Autoimmune Diseases
    Publication number: 20110008338
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 13, 2011
    Applicant: Genentech, Inc.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Treatment of Autoimmune Diseases
    Publication number: 20110008336
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 13, 2011
    Applicant: Genentech, Inc.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Treatment of autoimmune diseases
    Patent number: 7820161
    Abstract: Methods are disclosed of treating rheumatoid arthritis in a human comprising administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab and administering methotrexate to the human.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: October 26, 2010
    Assignees: Biogen Idec, Inc., Genentech, Inc.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies
    Publication number: 20100080769
    Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.
    Type: Application
    Filed: December 2, 2009
    Publication date: April 1, 2010
    Applicants: BIOGEN IDEC INC., GENENTECH, INC.
    Inventors: Antonio J. Grillo-Lopez, Christine A. White, John G. Curd, Susan Desmond-Hellmann
  • Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
    Patent number: 7682612
    Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: March 23, 2010
    Assignees: Biogen Idec Inc., Genentech, Inc.
    Inventors: Christine A. White, Antonio J. Grillo-López, John G. Curd, Susan Desmond-Hellmann
  • BLOCKING IMMUNE RESPONSE TO A GRAFT
    Publication number: 20100003252
    Abstract: The present application describes methods for blocking immune response to foreign antigens in a mammal using antagonists which bind to CD20.
    Type: Application
    Filed: September 8, 2009
    Publication date: January 7, 2010
    Applicants: Genentech, Inc., Biogen Idec Inc.
    Inventors: Antonio J. Grillo-Lopez, Lori A. Kunkel, Mark D. Pescovitz
  • USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT
    Publication number: 20090074760
    Abstract: The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.
    Type: Application
    Filed: April 9, 2008
    Publication date: March 19, 2009
    Inventors: ANTONIO J. GRILLO-LOPEZ, John Leonard